- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
AI-Powered Drug Marketer Medvi Responds to Allegations of Fake Doctors and Patients
Medvi's response raises more questions about its marketing practices and FDA compliance.
Apr. 9, 2026 at 10:07pm
Got story updates? Submit your updates here. ›
The neon-lit outline of a medical drug container symbolizes the ethical concerns surrounding Medvi's AI-powered marketing tactics in the healthcare industry.NYC TodayThe New York Times recently published a profile of the drug marketing company Medvi, which has been accused of using AI-generated images of fake patients and doctors in its advertising. In response to the backlash, Medvi has issued a statement claiming that the issues were isolated to an affiliate marketing agency, not Medvi itself. However, the company's response fails to address ongoing concerns about its use of misleading marketing tactics and potential violations of FDA regulations.
Why it matters
Medvi's business model and marketing practices raise significant ethical concerns, as the company has been accused of using deceptive tactics like AI-generated patient photos and fake doctor endorsements to promote its products. These issues are particularly problematic in the healthcare industry, where transparency and truthfulness are crucial. The company's response also raises questions about its relationship with the FDA and its commitment to operating ethically and transparently.
The details
Medvi is a drug marketing company that effectively operates as a wrapper for telehealth companies, prescribing and fulfilling orders for GLP-1 agonists and other compounded drugs. The company has been accused of a range of dishonest marketing practices, including using AI-deepfaked images of phony patients, flaunting media logos insinuating editorial coverage it didn't receive, and featuring the name and likeness of a medical practitioner who said he had nothing to do with the company. In February 2026, Medvi LLC was issued a warning from the FDA for misleading consumers on its Medvi.io website. In response to the backlash, Medvi has claimed that the issues were isolated to an affiliate marketing agency, not Medvi itself. However, the company's response fails to address ongoing concerns about its use of misleading marketing tactics and potential violations of FDA regulations on its own Medvi.org website.
- In February 2026, Medvi LLC was issued a warning from the Food and Drug Administration (FDA) for misleading consumers on its Medvi.io website.
- In December 2025, the FDA warning said Medvi.io was in violation of FDA guidelines.
The players
Medvi LLC
A drug marketing company that effectively operates as a wrapper for telehealth companies, prescribing and fulfilling orders for GLP-1 agonists and other compounded drugs.
Matthew Gallagher
The 41-year-old founder of Medvi.
Dr. Jon Slotkin
A neurosurgeon and hospital executive who commented on the dubious nature of Medvi's compounded oral tirzepatide product.
What they’re saying
“Why don't I just compound a little piece of cardboard and give it to you? There is exactly as much human data published that oral tirzepatide will help you lose weight as there is published data that compounded cardboard in a little tablet will help you lose weight. They're identical in their amount of evidence.”
— Dr. Jon Slotkin, Neurosurgeon and hospital executive
“Building a company the size of MEDVi and scaling so quickly involves many learning moments. At each of these stages, I have course-corrected immediately and appropriately. I will continue to do so.”
— Matthew Gallagher, Founder of Medvi
“As I continue helping our customers achieve their health goals, I remain committed to building and operating transparently.”
— Matthew Gallagher, Founder of Medvi
What’s next
Medvi's response raises more questions about the company's marketing practices and compliance with FDA regulations. It remains to be seen whether Medvi will fully address the concerns raised by journalists and the public, and whether the company will make meaningful changes to its business model and advertising tactics.
The takeaway
Medvi's use of deceptive marketing tactics, including AI-generated patient photos and fake doctor endorsements, highlights the need for greater transparency and accountability in the healthcare industry. The company's response, which fails to fully address these issues, raises concerns about its commitment to ethical business practices and compliance with regulatory standards.
